{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:04:30Z","timestamp":1792091070865,"version":"4.4.0"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100017624","name":"Achaogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017624","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR002002"],"award-info":[{"award-number":["KL2TR002002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,8,20]]},"abstract":"<jats:p>The gentamicin drug product is a complex mixture of numerous components, many of which have not individually undergone safety and efficacy assessments. This is in contrast to the majority of medicines that require rigorous characterizations of trace impurities and are dosed as single components. In gentamicin, four components, known as gentamicin congeners C1, C1a, C2, and C2a, comprise the majority of the mixture. A liquid chromatography-mass spectroscopy analysis revealed that the relative abundances of each gentamicin congener in commercial formulations can vary up to 1.<\/jats:p>","DOI":"10.1128\/aac.00533-20","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T14:28:20Z","timestamp":1593527300000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Unraveling the Gentamicin Drug Product Complexity Reveals Variation in Microbiological Activities and Nephrotoxicity"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-911X","authenticated-orcid":false,"given":"Zackery P.","family":"Bulman","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Cirz","sequence":"additional","affiliation":[{"name":"Achaogen Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"Achaogen Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Kane","sequence":"additional","affiliation":[{"name":"Achaogen Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuelay","family":"Rosario","sequence":"additional","affiliation":[{"name":"Achaogen Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Wlasichuk","sequence":"additional","affiliation":[{"name":"Achaogen Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjong","family":"Park","sequence":"additional","affiliation":[{"name":"Achaogen Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5092-4530","authenticated-orcid":false,"given":"Logan D.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Achaogen Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Critically important antimicrobials for human medicine, 6th revision","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Critically important antimicrobials for human medicine, 6th revision. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.05.027"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.04.002"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1365\/s10337-010-1763-y"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005101124"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.57.1.138-163.1993"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1994.tb06654.x"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2010.08.003"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky344"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.174.10.3196-3203.1992"},{"key":"e_1_3_3_12_2","volume-title":"WHO critically important antimicrobials for human medicine, 5th revision","author":"WHO","year":"2016","unstructured":"WHO. 2016. WHO critically important antimicrobials for human medicine, 5th revision. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/149.4.605"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-3-352"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014010035"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.83"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015010060"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1027372416983"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2008.9"},{"key":"e_1_3_3_20_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 29th informational supplement M100-S29","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing: 29th informational supplement M100-S29. CLSI, Wayne, PA."},{"key":"e_1_3_3_21_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters version 9.0. http:\/\/www.eucast.org."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2017.1316193"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.02.009"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-14"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3854-1"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0003-9"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90486-9"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00702.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109959200"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.19.159"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.35.11.2173"},{"key":"e_1_3_3_32_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. CLSI, Wayne, PA.","edition":"9"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262"},{"key":"e_1_3_3_34_2","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"2011","unstructured":"National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.","edition":"8"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01929-07"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(95)00584-1"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00533-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00533-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:00:08Z","timestamp":1645480808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00533-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8,20]]}},"alternative-id":["10.1128\/AAC.00533-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00533-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"2020-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00533-20"}}